For the WikiDoc page for this topic, click here
Hepatitis C |
Hepatitis C On the Web |
---|
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]
Hepatitis C is a contagious liver disease caused by the hepatitis C virus: the virus can cause both acute and chronic hepatitis infection, ranging in severity from a mild illness, lasting a few weeks to a serious, lifelong illness. The hepatitis C virus is a bloodborne virus and the most common modes of infection are through unsafe injection practices; inadequate sterilization of medical equipment in health-care settings; and unscreened blood and blood products. Today, most people become infected with the hepatitis C virus by sharing needles or other equipment to inject drugs. Acute HCV infection is usually asymptomatic, and is only very rarely associated with life-threatening disease. About 15–45% of infected persons spontaneously clear the virus within 6 months of infection without any treatment. The remaining 55–85% of persons will develop chronic HCV infection. Of those with chronic HCV infection, the risk of cirrhosis of the liver is 15–30% within 20 years. Hepatitis C can be either “acute” or “chronic.” Possible complication include: chronic hepatitis, liver failure and coma.
The incubation period for hepatitis C is 2 weeks to 6 months. When first infected with the hepatitis C virus many people may not feel ill. Approximately 70%–80% of people with acute hepatitis C do not have any symptoms. Others may find their urine becomes dark and their eyes and their skin may turn yellow (jaundice) or they may experience a minor ‘flu-like’ illness. Other symptoms of acute hepatitis C include:
These symptoms may disappear within a few weeks, but this does not necessarily mean that the infection has also gone.
If you have hepatitis symptoms, or think you have been put at risk, you should consult your doctor. A blood test can determine if you have hepatitis C. When a person has the virus for more than six months the illness is called chronic hepatitis C.
Most people with chronic hepatitis C do not have any symptoms. However, if a person has been infected for many years, his or her liver may be damaged. In many cases, there are no symptoms of the disease until liver problems have developed. In persons without symptoms, hepatitis C is often detected during routine [[blood tests≠≠ to measure liver function and liver enzymes (protein produced by the liver) level. The symptoms of chronic hepatitis C may be:
In many cases people who have chronic hepatitis C may not feel ill.
Even if a person with hepatitis C has no symptoms, he or she can still spread the virus to others.
The hepatitis C virus is present in the blood of an infected person. If infected blood enters another person’s blood stream, that person may get the virus. People can get hepatitis C by:
Mothers with hepatitis C may on rare occasions pass the virus to their babies during pregnancy, or at the time of birth. Breastfeeding is considered safe and only cracked or bleeding nipples may be a problem.
Sexual transmission rates of hepatitis C are very low, but the risk is increased with certain sexual practices or circumstances where there is the possibility of blood-to-blood contact (for example, sex during menstruation). The risk increases for those who have multiple sex partners, have a sexually transmitted disease, or are infected with HIV.
Early diagnosis can prevent health problems that may result from infection, and prevent transmission of the virus.
Some countries recommend screening for people who may be at increased risk of infection.
People in increased risk for hepatitis C infection, include:
Talk to your doctor about being tested for hepatitis C if any of the following are true:
Due to the fact that acute HCV infection is usually asymptomatic, early diagnosis of the HCV infection is rare. In those people who develop chronic HCV infection, the infection may remain undiagnosed, often until serious liver damage has developed.
HCV infection is diagnosed in 2 steps:
After a person has been diagnosed with chronic hepatitis C infection, they should have an assessment of the degree of liver damage (fibrosis and cirrhosis). This can be done by liver biopsy or through a variety of non-invasive tests.
In addition, these persons should have a laboratory test to identify the genotype of the hepatitis C strain. There are 6 genotypes of the HCV and they respond differently to treatment. Furthermore, it is possible for a person to be infected with more than one genotype. The degree of liver damage and virus genotype are used to guide treatment decisions and management of the disease.
Chronic hepatitis C is a serious disease that can result in long-term health problems, including liver damage, liver failure, liver cancer, or even death.
It is the leading cause of cirrhosis and liver cancer and the most common reason for liver transplantation in the United States. Approximately 8,000–10,000 people die every year from hepatitis C related liver disease.
Of every 100 people infected with the hepatitis C virus, about:
Some people who have hepatitis C choose to make changes to their lives, such as reducing alcohol intake, maintaining a well balanced diet that is low in fat and considering overall health maintenance.
You should also:
If you have hepatitis C you should not:
Although there is no legal obligation to do so, you may wish to discuss your condition with your health care provider (doctor, dentist, naturopath) for optimal health care.
Hepatitis C does not always require treatment as the immune response in some people will clear the infection. When treatment is necessary, the goal of hepatitis C treatment is cure. The cure rate depends on several factors including the strain of the virus and the type of treatment given. Careful screening is necessary before starting the treatment to determine the most appropriate approach for the patient.
The current standard treatment for hepatitis C is combination of antiviral therapy with interferon and ribavirin, which are effective against all the genotypes of hepatitis viruses (pan-genotypic).
Unfortunately, interferon is not widely available globally and it is poorly tolerated in some patients. This means that management of the treatment is complex, and many patients do not finish their treatment. Despite these limitations, interferon and ribavirin treatment can be life-saving.
Scientific advances have led to the development of new antiviral drugs for hepatitis C, which are much more effective, safer and better-tolerated than existing therapies.
These therapies, known as oral directly acting antiviral agent (DAAs) therapies simplify hepatitis C treatment by significantly decreasing monitoring requirements and by increasing cure rates. Although the production cost of DAAs is low, the initial prices set by companies are very high and likely to make access to these drugs difficult even in high-income countries.
Much needs to be done to ensure that these advances lead to greater access to treatment globally.
Possible complications of hepatitis C include:
Directions to Hospitals Treating Hepatitis C
There is no vaccine for hepatitis C, therefore prevention of HCV infection depends upon reducing the risk of exposure to the virus in health-care settings, in higher risk populations, for example, people who inject drugs, and through sexual contact.
The following list provides a limited example of primary prevention interventions recommended by WHO:
For people infected with the hepatitis C virus, WHO recommends: